IRIS Ultimaster Cohort in the IRIS-DES Registry
Launched by DUK-WOO PARK, MD · Mar 21, 2016
Trial Information
Current as of May 20, 2025
Active, not recruiting
Keywords
ClinConnect Summary
The IRIS Ultimaster Cohort study is looking at how well the Ultimaster stent works compared to other similar stents that release medication to help keep arteries open. This is important for patients with coronary artery disease, a condition where the heart's arteries become narrow or blocked. The trial is currently active but not recruiting new participants, meaning they are not looking for new volunteers right now.
To be eligible for this study, participants need to be at least 19 years old and agree to use the Ultimaster stent. However, people who are expected to live less than a year, are experiencing severe heart problems, or who are getting multiple stents at the same time are not able to join. If someone is part of this study, they can expect to have their health closely monitored to see how well the stent works and if there are any safety concerns. This research is important because it will help doctors understand the best options for treating coronary artery disease.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 19 and more
- • Intervention with Ultimaster stent
- • Agreed with written informed consent form
- Exclusion Criteria:
- • Intervention with Ultimaster stent and other drug eluting stent at the same time
- • Life expectancy of 1year and under
- • Cardiac shock
About Duk Woo Park, Md
Dr. Duk-Woo Park, MD, is a distinguished clinical trial sponsor renowned for his commitment to advancing medical research and improving patient outcomes. With extensive experience in clinical medicine and trial management, Dr. Park leads innovative studies that explore cutting-edge therapies and treatment modalities. His collaborative approach fosters partnerships with leading institutions and research organizations, ensuring rigorous adherence to ethical standards and regulatory compliance. Driven by a passion for enhancing healthcare, Dr. Park is dedicated to translating scientific discoveries into practical applications that benefit patients and the broader medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Daegu, , Korea, Republic Of
Incheon, , Korea, Republic Of
Ulsan, , Korea, Republic Of
Daegu, , Korea, Republic Of
Kwangju, , Korea, Republic Of
Daegu, , Korea, Republic Of
Busan, , Korea, Republic Of
Pusan, , Korea, Republic Of
Gangneung, , Korea, Republic Of
Ilsan, , Korea, Republic Of
Chuncheon, , Korea, Republic Of
Seoul, , Korea, Republic Of
Bucheon, , Korea, Republic Of
Suwon, , Korea, Republic Of
Seoul, , Korea, Republic Of
Wonju, , Korea, Republic Of
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials